<DOC>
	<DOCNO>NCT00362258</DOCNO>
	<brief_summary>- To evaluate Blood Pressure ( BP ) reduction target value ( Systolic BP ≤ 130 mmHg Diastolic BP ≤ 80 mmHg ) hypertensive type 2 diabetic patient . - To evaluate benefit Irbesartan reduction microalbuminuria baseline ( inclusion visit ) population . - To demonstrate safety Irbesartan population .</brief_summary>
	<brief_title>I PREVENT - Irbesartan In Hypertensive Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Proven Hypertensive Type 2 Diabetic Patients HbA1c &gt; 6 % ≤ 10 % ( without microalbuminuria ) . Newly diagnose `` naïve '' hypertensive patient ( prior treatment hypertension ) . OR , Patients receive antihypertensive agent ( maximum two agent , include one diuretic ) blood pressure target achieve , yet , investigator 's opinion , patient would benefit switch study medication . These patient undergo wash period le 7 day prior enrollment . Severe hypertension ( SBP ≥ 180 mm Hg DBP ≥ 110 mm Hg ) . Patients secondary hypertension . Patients UAE &gt; 200µg / min . Patients HbA1c &lt; 6 % &gt; 10 % . Significant chronic renal impairment ( Serum creatinine &gt; 2.0 mg/dL ) . Significant liver disease show SGPT/SGOT ( ALAT/ASAT ) &gt; 2.5 time upper limit normal range . Currently pregnant lactating female . Women childbearing potential protected effective contraceptive method birth control and/or unwilling unable test pregnancy . Any patient need combination antihypertensive therapy start ( medical point view his/her physician ) . Known hypersensitivity irbesartan , ARBs ( Angiotensin Receptor Blockers ) , hydrochlorothiazide , thiazide diuretic . Patients malignancy past 5 year , know collagen disease severe cardiac , cerebrovascular gastric disease . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>